EcoDrugPlus

Bruton Tyrosine Kinase

Ensembl ID : ENSSHAG00000013506
Gene Symbol: BTK
2 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Chemokine Receptor Type 5

Ensembl ID : ENSSHAG00000027576
Gene Symbol: LOC100913351
3 Cross references
370 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Chemokine Receptor Type 5-Like

Ensembl ID : ENSSHAG00000021136
Gene Symbol: LOC100913616
3 Cross references
369 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSSHAG00000000227
Gene Symbol: CCR1
4 Cross references
299 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSSHAG00000001777
Gene Symbol: CCR4
3 Cross references
254 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Chemokine Receptor Type 1

Ensembl ID : ENSSHAG00000025920
Gene Symbol: LOC100921946
3 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Chemokine Receptor Type 2

Ensembl ID : ENSSHAG00000030658
Gene Symbol: LOC100922206
3 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSSHAG00000015957
Gene Symbol: CXCL8
4 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSSHAG00000008142
Gene Symbol: CXCR4
4 Cross references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna (Cytosine-5)-Methyltransferase 1

Ensembl ID : ENSSHAG00000008894
Gene Symbol: LOC100934323
3 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase I

Ensembl ID : ENSSHAG00000017836
Gene Symbol: TOP1
4 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSSHAG00000012147
Gene Symbol: TOP2A
4 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).